Baby Formula NEC Lawsuits: Premature Infant Injury Claims Linked to Similac and Abbott Laboratories

Legal information resource. CredibleLaw is an attorney referral network, not a law firm. This article is for educational purposes only and is not legal advice.

---

Families across the United States are pursuing lawsuits alleging that cow’s milk-based infant formulas used in neonatal intensive care units contributed to necrotizing enterocolitis — a severe and often fatal intestinal disease that primarily affects premature infants. The litigation centers on two manufacturers: Abbott Laboratories, which makes the Similac line, and Mead Johnson, a Reckitt subsidiary that makes Enfamil. Plaintiffs allege that both companies knew their cow’s milk-based preterm formulas carried a heightened NEC risk for premature babies and that they failed to warn hospitals, clinicians, or families.

The cases involve devastating injuries. Necrotizing enterocolitis can cause intestinal tissue to die, trigger life-threatening systemic infection, force emergency bowel surgery, leave survivors with lifelong digestive and developmental complications, and — in a significant percentage of cases — end in the infant’s death. NEC has an estimated mortality rate of more than 20% and affects the bowel tissue of newborns, primarily premature infants. Insurance Journal

As of April 2026, 782 Similac and Enfamil lawsuits are pending in the federal multidistrict litigation, MDL 3026, before U.S. District Judge Rebecca Pallmeyer in the Northern District of Illinois. Drugwatch Hundreds more cases are moving through state courts. Jury verdicts in state trials have already reached into the hundreds of millions of dollars, including a Missouri verdict against Abbott in 2024 and a Cook County verdict handed down in April 2026. This article explains what NEC is, why the lawsuits are being filed, where the litigation stands now, and what families affected by the disease should understand about the claims process.

What Is Necrotizing Enterocolitis (NEC)?

Necrotizing enterocolitis is a serious gastrointestinal emergency that most often strikes premature infants in the first weeks of life. The disease involves inflammation of the intestinal lining, followed by death of intestinal tissue — the “necrotizing” part of the name. In severe cases, the bowel wall can perforate, allowing bacteria and intestinal contents to enter the abdominal cavity and trigger sepsis.

Premature infants are uniquely vulnerable. Their immune systems are underdeveloped. Their intestinal lining is thinner and more permeable than a full-term baby’s. The normal bacterial colonization of their gut is disrupted by NICU antibiotics and by the artificial feeding environment itself. Any feeding that is not well tolerated can trigger an inflammatory cascade that, once started, is extremely difficult to stop.

Symptoms of NEC can include abdominal swelling, feeding intolerance, bloody stools, lethargy, temperature instability, and signs of shock. Diagnosis typically involves abdominal imaging that shows air in the intestinal wall — a hallmark finding called pneumatosis intestinalis.

Treatment depends on severity. Early-stage NEC may be managed with bowel rest, intravenous nutrition, and antibiotics. More advanced cases require emergency surgery to remove necrotic bowel. Infants who lose significant portions of their intestine can develop short bowel syndrome and require long-term specialized nutrition. Survivors often face ongoing digestive complications, feeding difficulties, neurodevelopmental delays, and repeated hospitalizations. For many families, NEC is not a discrete event but the beginning of years of medical care.

Why Are Parents Filing Baby Formula NEC Lawsuits?

The core legal theory in the baby formula NEC litigation is a failure-to-warn claim. Plaintiffs allege that Abbott Laboratories and Mead Johnson knew, or should have known, that their cow’s milk-based formulas and fortifiers posed a heightened NEC risk for premature infants, and that the companies nonetheless marketed those products for use in NICUs without adequately warning hospitals, clinicians, or families about that risk.

The complaints generally argue that the manufacturers were aware of medical literature linking cow’s milk-based feeding to elevated NEC rates in premature infants, that alternative feeding strategies — including exclusive human milk diets using donor milk and human milk-based fortifiers — were available, and that the companies continued to promote their products as safe and medically necessary for NICU use despite that knowledge. Many suits also include claims for design defect and negligence in the manufacture, testing, and marketing of the formulas.

Defendants dispute these allegations. Abbott and Mead Johnson maintain that their products are safe and essential for premature infants whose mothers cannot produce sufficient breast milk, that the medical and regulatory consensus does not establish a causal link between formula and NEC, and that prematurity itself — not formula feeding — is the principal risk factor. The FDA has not concluded that cow’s milk-based formulas cause NEC, and a 2024 joint report from the NIH working group and federal regulators stated that current evidence supports the hypothesis that the absence of breast milk, rather than exposure to formula, is associated with increased NEC incidence. Insurance Journal

Courts are still sorting through the competing expert evidence, and outcomes have varied significantly depending on the specific case, the forum, and the quality of the expert testimony offered on causation.

Which Baby Formula Products Are Involved?

The lawsuits focus on cow’s milk-based formulas and human milk fortifiers marketed for use with premature infants — the products most commonly used in NICUs when mother’s own milk is unavailable or insufficient.

The Abbott products named in the litigation include Similac Special Care, Similac Special Care 24, Similac NeoSure, and Similac Human Milk Fortifier. These are Abbott’s preterm-focused product line. The Mead Johnson products named include Enfamil Premature, Enfamil Premature 20 Cal, and Enfamil Human Milk Fortifier. Abbott’s Similac product line has generated a large share of the claims because of Abbott’s substantial market share in preterm infant nutrition.

The litigation is distinct from Abbott’s separate Cronobacter contamination cases. Judge Matthew Kennelly presides over a separate Abbott MDL, MDL 3037, which involves bacterial contamination of Abbott baby formulas and is unrelated to NEC claims. Consumer Notice Families pursuing NEC claims should be careful to distinguish between the two proceedings.

Major Verdicts and Developments in Baby Formula NEC Litigation

The state-court docket has generated the most headline-grabbing outcomes in the litigation so far, and the verdicts illustrate how sharply juries have divided when they evaluate the underlying evidence.

March 2024 — $60 million against Mead Johnson (Illinois). A St. Clair County, Illinois jury awarded $60 million to the mother of a premature infant who died after being fed Enfamil. The verdict was the first trial ever to hold a cow’s milk-based formula manufacturer accountable for causing NEC in a premature infant. PR Newswire The case has been appealed.

July 2024 — $495 million against Abbott (Missouri). A St. Louis jury returned one of the largest pharmaceutical product liability verdicts of the year, awarding $95 million in compensatory damages and $400 million in punitive damages to the family of an infant who developed NEC after being fed Abbott’s preterm formula in a NICU. The verdict has been appealed.

October 2024 — defense verdict (Missouri). A separate St. Louis jury sided with Abbott and Reckitt, rejecting NEC claims against both companies in a case involving the same family of products. The defense verdict interrupted the plaintiffs’ momentum and underscored how much the evidence in any single case drives the outcome.

April 2026 — $70 million against Abbott (Cook County, Illinois). In the most recent high-profile verdict, a Cook County jury awarded $53 million in compensatory damages and $17 million in punitive damages to four Chicago-area families whose premature infants developed NEC after being fed Similac Special Care in NICUs. The case, Mendez v. Abbott Laboratories, was the first Illinois state court verdict against Abbott in the NEC litigation and the first time multiple NEC formula claims were tried together. The jury found Abbott liable for product defect, failure to warn, and negligence. Abbott has said it will appeal.

Federal bellwether status. The federal MDL has moved more slowly than the state courts, and the early results have favored the defendants. Judge Pallmeyer granted Abbott summary judgment in the first three federal bellwether trials after finding the plaintiffs failed to establish a feasible alternative to cow’s milk-based formula at the scale required to meet NICU demand. Verus LLC In the same rulings, however, the judge declined to exclude the plaintiffs’ general causation experts and rejected Abbott’s argument that it had no duty to warn — two rulings plaintiffs’ counsel have said leave the door open for future bellwethers to proceed.

Second wave of bellwethers. A second wave of MDL bellwether trials has been tentatively scheduled for August 2026, November 2026, and February 2027, with hundreds of state court cases continuing to move forward in parallel. Helbocklaw

Abbott has also signaled that continued adverse verdicts could prompt the company to reconsider whether it continues to sell certain preterm infant formulas in the U.S. market, and the company has lobbied Congress for federal liability protections — proposals that have drawn pushback from lawmakers and from attorneys representing affected families.

Multidistrict Litigation (MDL) and Federal Baby Formula Cases

Federal NEC baby formula cases have been consolidated since April 2022 in MDL 3026, officially captioned In re Abbott Laboratories, et al., Preterm Infant Nutrition Products Liability Litigation. Judge Rebecca Pallmeyer, Chief Judge of the Northern District of Illinois at the time of consolidation, presides.

Multidistrict litigation is a federal procedural mechanism, not a class action. In an MDL, individual lawsuits filed in federal courts across the country are transferred to a single district for coordinated pretrial proceedings — principally discovery, motion practice, and bellwether trials. Each case retains its own plaintiff, its own facts, and its own damages; only the pretrial work is consolidated.

The purpose of MDL consolidation is efficiency. Rather than hundreds of judges handling overlapping discovery disputes and Daubert challenges on the same underlying science, a single judge manages the threshold issues and the parties use a small set of bellwether trials to test how juries respond to the representative evidence. Bellwether verdicts are not binding on the other cases, but they strongly influence settlement negotiations.

In MDL 3026, the early federal bellwether results have tilted toward the defense. The judge’s summary judgment rulings in the first three cases turned heavily on the “no feasible alternative” argument — Abbott’s position that there is no practical substitute for cow’s milk-based formula at NICU scale — and on challenges to plaintiffs’ specific causation evidence under the Daubert standard. At the same time, the judge preserved the plaintiffs’ general causation experts and rejected key defense arguments about duty to warn, which means the second wave of bellwether trials will proceed on a different evidentiary record than the first three.

Who May Qualify for a Baby Formula NEC Lawsuit?

Eligibility criteria vary by case, but the core factual requirements are consistent across the litigation. Potential claims typically require that the child was born prematurely — most firms use 37 weeks’ gestational age as the cutoff, with many focusing on very premature infants under 32 weeks; that the child was fed a cow’s milk-based infant formula or human milk fortifier, usually while in a hospital NICU; that the child developed necrotizing enterocolitis during or shortly after formula feeding; and that medical records confirm both the NEC diagnosis and the feeding history.

Claims are brought by parents, legal guardians, or — in wrongful death cases — the estate of the deceased infant. Statutes of limitations vary by state and by claim type, and can be particularly complex when the injured child is still a minor. Families who believe they may have a claim should consult an attorney promptly rather than assume any deadline applies uniformly.

Documentation matters. Medical records establishing the preterm birth, the NICU feeding regimen, the NEC diagnosis and treatment, and any surgical intervention or long-term complications are foundational to any claim. Families who still have formula packaging, hospital discharge summaries, or receipts should preserve them.

Potential Compensation in NEC Lawsuits

Damages sought in NEC baby formula cases typically include past and future medical expenses (including NICU charges, surgical costs, and long-term care), pain and suffering, loss of a normal life, emotional distress, and — in fatal cases — wrongful death damages under the applicable state’s statute. Cases involving allegations of willful or particularly egregious corporate conduct may also support punitive damages, as reflected in the Missouri and Chicago verdicts.

Settlement projections vary widely, and no global settlement has been reached or approved. Individual case values depend heavily on the severity of injury, whether the child survived, the extent of ongoing medical needs, the strength of the causation evidence, and the forum. State court verdicts have so far produced some of the largest individual awards, but those verdicts are all on appeal and the final recoveries remain uncertain. Any attorney representation on these cases must comply with the applicable rules of professional conduct, and families should be wary of any firm that guarantees a specific outcome or settlement amount.

Scientific Debate and Manufacturer Defenses

The scientific dispute at the heart of this litigation is genuinely contested, and it is worth understanding on its own terms.

Manufacturers deny that their products cause NEC. Their defenses center on several themes. NEC is strongly associated with prematurity itself, independent of feeding practice. Cow’s milk-based formula and fortifier are medically necessary when maternal milk is unavailable, and no adequate alternative exists at scale. Regulatory agencies, including the FDA, have not determined that cow’s milk-based preterm formulas cause NEC. And a 2024 joint NIH-led report concluded that the protective factor is the presence of breast milk rather than the absence of formula — a framing that shifts the causal emphasis away from the formula products.

Plaintiffs counter that the medical literature supports a causal association between cow’s milk-based feeding and elevated NEC rates in premature infants, that the manufacturers have long been aware of that association, that human milk-based alternatives (including donor milk and human milk-based fortifiers) are available for at least a subset of infants, and that the companies’ failure to warn hospitals and families deprived them of the information needed to make informed feeding decisions. The American Academy of Pediatrics has publicly reaffirmed that mothers’ own milk, properly fortified, is the optimal nutrition for very low birth weight infants, while also filing an amicus brief supporting Mead Johnson’s appeal of the 2024 Illinois verdict.

The conflicting verdicts across courts reflect the genuine difficulty juries face in evaluating this evidence. Cases with stronger specific causation evidence, more documented internal knowledge on the part of the defendant, and more severe injuries have tended to produce plaintiff verdicts. Cases with thinner causation evidence or less dramatic factual records have produced defense verdicts or summary judgment rulings.

What Families Should Know About Filing an NEC Lawsuit

The litigation process in a baby formula NEC case generally follows a predictable structure. An attorney evaluates the family’s records — medical, feeding, and NICU documentation — to confirm that the core factual requirements are met. If the case is viable, the complaint is filed in the appropriate forum, which may be a federal court (in which case the case is likely to be transferred into MDL 3026) or a state court where venue and jurisdiction are established. The case then proceeds through discovery, expert reports, and motion practice, with the possibility of bellwether consideration in the MDL or trial scheduling in state court.

Statutes of limitations are a critical early issue. They are generally longer for minors than for adults, but they vary by state and by claim theory, and tolling rules do not apply uniformly. Families who suspect a possible claim should not wait to consult counsel.

Settlement discussions are influenced heavily by bellwether outcomes and by the trajectory of state court verdicts. No master settlement has been reached in MDL 3026, and the pace of any future global resolution depends on the second wave of bellwether trials and on how the state court appellate courts rule on the 2024 and 2026 verdicts.

Related Mass Tort Lawsuits Covered by CredibleLaw

The baby formula NEC litigation is part of a broader wave of pharmaceutical and consumer product mass torts in which manufacturers are facing allegations of failure to warn, design defect, or deceptive marketing. Related cases covered on CredibleLaw include the Suboxone tooth decay litigation, the PFAS water contamination lawsuits, the Paraquat Parkinson’s disease lawsuits, and the hair relaxer cancer lawsuits. On the corporate accountability side, CredibleLaw also covers the OpenAI copyright litigation and the Google antitrust monopoly litigation, which involve different substantive claims but reflect the same underlying pattern of large-scale litigation driving corporate transparency and accountability.

The Future of Baby Formula NEC Litigation

Several developments will shape the next phase of the litigation. The second wave of federal bellwether trials, beginning in August 2026, will test whether plaintiffs can clear the Daubert and summary judgment hurdles that sank the first three bellwethers. Appellate rulings in Illinois and Missouri on the 2024 state court verdicts will clarify the scope of liability theories available to plaintiffs and could reshape settlement dynamics across the MDL. The April 2026 Chicago verdict in Mendez v. Abbott adds new pressure on the defense side and may influence how future consolidated state court trials are managed.

Regulatory developments are also worth watching. The FDA has not concluded that cow’s milk-based preterm formulas cause NEC, but ongoing scientific review, new clinical guidelines from professional societies, and any legislative action on federal liability protections could all shift the landscape. Abbott’s public statements that it might exit the preterm formula market if verdicts continue to mount introduce a supply-side dimension that regulators, clinicians, and legislators are taking seriously.

Frequently Asked Questions About Baby Formula NEC Lawsuits

What is NEC?

Necrotizing enterocolitis is a severe gastrointestinal disease affecting primarily premature infants, in which intestinal tissue becomes inflamed and begins to die. Severe cases can perforate the bowel, trigger systemic infection, and require emergency surgery to remove necrotic tissue. NEC carries a significant mortality rate and can leave survivors with lifelong complications.

Can baby formula cause NEC?

The question is scientifically contested and is at the center of this litigation. Plaintiffs argue that cow’s milk-based formulas and fortifiers increase the NEC risk for premature infants. Manufacturers and federal regulators have not concluded that the formulas cause NEC, and a 2024 NIH working group report emphasized the absence of breast milk as the relevant factor. Courts are still evaluating expert evidence, and verdicts have split in both directions.

Who can file a baby formula lawsuit?

Eligibility generally requires that the child was born prematurely, was fed a cow’s milk-based formula or human milk fortifier (typically in a NICU), was diagnosed with NEC, and has medical records documenting both the diagnosis and the feeding history. Claims may be filed by parents, legal guardians, or, in wrongful death cases, the infant’s estate. Statutes of limitations vary by state and should be evaluated with an attorney promptly.

What formulas are involved in NEC lawsuits?

The lawsuits focus on cow’s milk-based preterm formulas and human milk fortifiers. Abbott products named include Similac Special Care, Similac Special Care 24, Similac NeoSure, and Similac Human Milk Fortifier. Mead Johnson products named include Enfamil Premature, Enfamil Premature 20 Cal, and Enfamil Human Milk Fortifier.

How much compensation can families receive?

Compensation varies widely. Damages typically include past and future medical costs, pain and suffering, loss of a normal life, emotional distress, wrongful death damages where applicable, and punitive damages in cases involving allegations of particularly egregious conduct. State court verdicts have ranged from defense verdicts (zero recovery) to awards of hundreds of millions of dollars. No global settlement has been reached, and individual case values depend on the severity of injury, the strength of the causation evidence, and the forum. Any firm that guarantees a specific recovery should be approached with caution.

---

This article is provided for educational and informational purposes only. It is not legal advice and does not create an attorney-client relationship. CredibleLaw is an attorney referral network, not a law firm. For guidance specific to your family’s situation, consult a licensed attorney.